GoodRx Target of Unusually High Options Trading (NASDAQ:GDRX)

GoodRx Holdings, Inc. (NASDAQ:GDRX) saw some unusual options trading on Monday. Stock traders acquired 8,411 call options on the company. This is an increase of approximately 1,884% compared to the average volume of 424 call options.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Raymond James & Associates boosted its stake in GoodRx by 212.6% in the 3rd quarter. Raymond James & Associates now owns 394,006 shares of the company’s stock worth $2,734,000 after purchasing an additional 267,951 shares during the period. CWA Asset Management Group LLC acquired a new stake in shares of GoodRx during the 3rd quarter valued at $370,000. Quest Partners LLC acquired a new stake in shares of GoodRx during the 3rd quarter valued at $160,000. Charles Schwab Investment Management Inc. boosted its stake in shares of GoodRx by 5.8% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 480,123 shares of the company’s stock valued at $3,332,000 after buying an additional 26,262 shares during the period. Finally, Dynamic Technology Lab Private Ltd boosted its stake in shares of GoodRx by 260.7% during the 3rd quarter. Dynamic Technology Lab Private Ltd now owns 44,419 shares of the company’s stock valued at $308,000 after buying an additional 32,104 shares during the period. Institutional investors and hedge funds own 63.77% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on GDRX shares. Citigroup cut their price target on GoodRx from $7.00 to $6.25 and set a “buy” rating on the stock in a report on Friday, January 10th. Morgan Stanley cut their price target on GoodRx from $7.00 to $6.00 and set an “equal weight” rating on the stock in a report on Tuesday, December 17th. Mizuho started coverage on GoodRx in a report on Wednesday, December 4th. They set a “neutral” rating and a $5.00 price target on the stock. KeyCorp cut their price target on GoodRx from $7.00 to $6.00 and set an “overweight” rating on the stock in a report on Wednesday, January 8th. Finally, Barclays cut their price target on GoodRx from $10.00 to $6.00 and set an “overweight” rating on the stock in a report on Monday, November 11th. Five equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $8.38.

GoodRx Trading Up 0.6 %

GoodRx stock opened at $4.84 on Tuesday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 5.48 and a current ratio of 5.48. The firm has a market cap of $1.84 billion, a price-to-earnings ratio of -161.33, a price-to-earnings-growth ratio of 2.46 and a beta of 1.28. GoodRx has a 1 year low of $4.09 and a 1 year high of $9.26. The firm’s 50 day moving average price is $4.67 and its two-hundred day moving average price is $5.79.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.